Vascular malformations are localized defects of vascular development. They usually affect a limited number of vessels in a restricted area of the body. Although most malformations are sporadic, inheritance is observed, enabling genetic analysis.
Introduction
The blood and lymphatic vessels are made of a single layer of endothelial cells to be due to defects in these pathways (1) . Most malformations are present at birth and grow proportionately with the child. In inherited forms, new lesions can appear, but they stay small. The etiopathological genetic defects have been elucidated for some of these, and they are discussed here with relevant functional data and development of small animal models.
Venous malformations
Venous anomalies have an incidence estimated around 1/10,000 (2) . These slow-flow lesions are subdivided into venous malformations (95 %, including sporadic VM and VMCM, i.e. mucocutaneous VM), and glomuvenous malformations (GVM, 5%). Following identification of the causative genes for VMCM and GVM, criteria for differential diagnosis were established (3) . This has allowed better management. The etiopathogenesis of sporadic VM and syndromes which associate venous anomalies, including Blue Rubber Bleb Nevus syndrome (BRBN, MIM 112200), characterized by cutaneous and gastrointestinal VM, Maffucci syndrome (MIM 166000), and Klippel-Trenaunay syndrome (MIM149000) are unknown. The latter was suggested to be due to mutations in VG5Q (4) , but the reported nucleotide change was later shown to be a common polymorphism (5, 6) .
Cutaneomucosal venous malformation (VMCM) and sporadic Venous malformation (VM)
Venous Malformation (MIM 600195) presents as a bluish-hue lesion, mainly on skin and mucosa, commonly infiltrating the underlying muscle and joints ( Figure 1A ). It can be emptied by compression, it can be painful, but not on palpation, and sometimes it develops calcifications. Large size, involvement of underlying tissues and presence of calcifications is linked to localized intravascular coagulopathy (LIC) (7) . Although mostly sporadic (~ 98 %), VM follows autosomal dominant inheritance in VMCM (3) . On histology, enlarged vein-like channels, lined by a single layer of endothelial cells, present a patchy relative lack of surrounding vSMCs (8) . The current treatments include elastic stockings, sclerotherapy and surgery (9) .
The inherited VMCM is caused by mutations in the endothelial cell-specific receptor tyrosine kinase TIE2, also known as TEK, located in the VMCM1 locus on 9p21 (8) . Only two mutations have been reported: R849W in four families and Y897S in one (8, 10, 11) . We have identified six additional families with the R849W change and six with a novel substitution, all in the kinase domains (12) . All R849W changes are not due to a single founder allele, suggesting this change to be one of the rare changes able to cause VM while remaining compatible with germline transmission (12) . R849W and Y897S increase ligand-independent autophosphorylation of the receptor, without causing endothelial cell proliferation (8, 10) . Interestingly, we observed a somatic second-hit in TIE2 in a VM of a patient with inherited R849W mutation (12) . This, like the one reported in a GVM (13) , supports the idea that the inherited forms need a somatic alteration of the second allele for development of lesions.
Three TIE2 ligands are known: angiopoietins -1, -2 and -4, the latter corresponding to Angpt3 in mouse (14) (15) (16) . ANGPT1 activates tyrosine phosphorylation while ANGPT2 has a weaker effect and is considered as a competitive inhibitor of ANGPT1. Upon binding of the multimeric ligand, receptors dimerize and cross-phosphorylate, triggering mainly the PI3-kinase pathway, which activates AKT and inhibits apoptosis, and the MAP-kinase pathway ( Figure 2 ) (17).
Tie2-deficient mice die at mid-gestation with insufficient remodeling of the primary capillary plexus (14, 18) , and mice deficient in the catalytic subunit of the PI3K result in diminished Tie2 expression, with a strikingly similar phenotype (19). As survival, mediated by ShcA, is increased by mutant TIE2 (20), it may explain the relative excess of ECs in VM. ANGPT1, via TIE2, triggers vSMC recruitment by upregulation of hepatocyte growth factor secretion (21). HGF is also a survival factor for endothelial cells (22) but its role in VM is not known (Figure 2 hybridization and the identification of a double-hit mutation in a lesion, suggest paradominant inheritance (13, 27 ).
Glomulin expression is restricted to vascular smooth muscle cells (28) and is involved in their differentiation (27). When lacking, the precursors cells seem to be deviated towards the "glomus cell" phenotype. As transforming growth factor beta (TGFβ) signaling is crucial for vSMC differentiation, the alteration may be due to lack of glomulin to compete with the FKBP12 binding to TGFβ type I receptor 
Capillary malformation (CM)
Capillary malformations (MIM 163000) or "port-wine stains", are flat, redpurple, cutaneous lesions most frequently located in head and neck ( Figure 2C congestive heart failure (38, 39). PKWS has been considered sporadic or eventually due to post-zygotic mutations, but when associated with multifocal CMs, it is due to a germline RASA1 mutation.
CMs usually require no treatment but can be lasered. However, fast-flow lesions render CM-AVM dangerous and difficult to treat, but the identification of involvement of RASA1 gives hope for development of novel therapeutic approaches.
Most AVMs are sporadic, reflecting the severity of the defects that would probably result in early embryonic lethality if transmitted.
Reduced penetrance, and variable expressivity suggest a double-hit mechanism to be involved. The encoded protein, p120RasGAP negatively regulates the Ras/MAPkinase pathway ( Figure 2 ). Upon receptor tyrosine kinase activation, it is recruited to the plasma membrane, alone or by Annexin A6, to inactivate Ras (40).
It also interacts with p190RhoGAP to control cell motility (41), and binds to AKT to protect cells from apoptosis (42). It is not known which one(s) of the pathways is/are altered in CM-AVM (43). Rasa1 +/-mice are normal, while knockouts die at E10.5 due to defective vascular development and increased apoptosis (44).
Hereditary hemorrhagic telangiectasia (HHT)
Hereditary hemorrhagic telangiectasia (HHT, MIM 187300 and 600376) also Although Alk1 or Eng-deficient mice are lethal (60) (61) (62) (63) (64) , heterozygotes are viable, and some develop HHT-like lesions (65, 66) . ALK1 ligands involved in HHT seem to be BMP9 and BMP10 rather than TGFβ (Figure 2 ) (67, 68). They inhibit EC proliferation and migration (68) . The ubiquitously expressed SMAD4 is an intracellular TGFβ receptor signal transducer, but its knockout causes early lethality due to failure in gastrulation (69) . The HHT3 and 4 genes are likely other players in the same signaling pathway.
Cerebral cavernous malformation (CCM)
Cerebral cavernous (or capillary-venous) malformation (CCM, MIM 116860) has a prevalence of about 0.5 % (70). Seizures, headaches and neurological problems are the common symptoms, although many can be asymptomatic (71 Close to hundred mutations have been identified in CCM1, representing about 40 % of the CCM families (79) . Most result in loss-of-function, and double-hits have been discovered in two samples (80, 81) . In three families with KRIT1 mutations, the patients presented hyperkeratotic cutaneous capillary-venous malformations (HCCVM, MIM 116860) ( Figure 1E ) in addition to CCMs (82, 83) .
The function of the CCM proteins is starting to be unraveled. CCM1 RNA has been detected in astrocytes, neurons and various epithelial cells (84, 85) and the protein was detected in ECs of capillaries and arterioles in adult (86) . KRIT1
interacts with the α isoform of the β 1 -integrin cytoplasmic domain-associated protein 1, ICAP-1α (87, 88) , which participates in regulation of cell adhesion and migration ( Figure 2 ) (89, 90) . By competing with this interaction, KRIT1 may control endothelial cell behavior (90) . Conversely, ICAP-1α is able to sequester KRIT1 to the nucleus (87) . KRIT1 also associates with microtubules (91). Interestingly, Krit1
-/-embryos die at mid-gestation due to defective vascular development associated with downregulation of arterial markers (92) . The basic defect in CCM might thus be linked to arterial-venous specification.
Expression profiles of CCM2 and PDCD10 are similar to KRIT1, and CCM2
is also transiently expressed in mesenchymal and parenchymal vessels (86, 93, 94) .
The CCM2 protein contains a phosphotyrosine-binding domain similar to that of ICAP-1α and it is able to sequester KRIT1 in the cytoplasm (95) 
Lymphedema is also observed in Osteoporosis, Lymphedema, Anhydrotic
Ectodermal Dysplasia with Immunodeficiency syndrome, abbreviated OLEDAID, a rare syndrome associated with Incontinentia Pigmenti (MIM 308300). Replacement of the termination codon of the NFκB essential modulator IKBKG (NEMO, Xq28) by a tryptophane, was identified in two independent patients. The mutation leads to an enlarged protein with reduced NFκB activation (116, 117) . Ikbkg -/-mice die from severe apoptosis due to defective NFκB activity (118) . As VEGFR3 has been shown to activate NFκB it may be the pathway involved in Milroy disease. Lymphedema-cholestasis syndrome, also known as Aagenaes syndrome (MIM 214900), is an autosomal recessive disorder (119), although de novo autosomal dominant mutation was also suggested (120) . An haplotype-shared region has been identified in 15q (121) , and the search for the defective gene in ongoing.
Concluding remarks
The identification of several genes, mutations in which cause vascular malformations, has helped to better delineate the spectrum of signs and symptoms of each subtype and to newly recognize clinical entities. This is paving the way to understand their molecular etiopathogenesis, a fundamental step towards precise diagnosis and management.
Most defects disturb the function of vascular endothelial cells. Only in GVM the primary defect is in mural smooth muscle cells, and in CCM, it is not clear which cell types are affected by the primary defect. In addition, the pathogenic mechanisms that lead from the mutations to development of lesions are still far from being understood. Figure 2 schematizes the factors identified to be involved in vascular and lymphatic anomalies. All except the TIE2 mutations presumably result in nonfunctional alleles, which may cause either haploinsufficiency and/or dominantnegative effects.
An interesting question is the vessel-type specificity of the localized lesions.
Only peripheral small vessels are affected, and for exemple, the distribution of AVMs is different in CM-AVM, HHT1, HHT2 and PHTS. Thus, the mutated molecules must have vessel-type specific functions and/or interactions. The challenge is to define these and to identify the cells that express the proteins. For most of these genes, the homozygous murine knockout embryos are lethal, and the heterozygous animals are phenotypically normal. Yet, the patients with familial vascular anomalies mostly carry a germline heterozygous mutation. Therefore, obtention of good animal models to understand the pathophysiological processes and to develop novel therapies, will probably require inducible conditional targeting, underscoring the likelihood that the double-hit mechanism could explain the localized nature, multifocality, varied expressivity, and penetrance that reaches its maximum towards puberty, of these lesions. 
